Yanling Feng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4064188/publications.pdf

Version: 2024-02-01

		1040056	794594
19	418	9	19
papers	citations	h-index	g-index
20	20	20	702
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 439-449.	10.7	115
2	Prognostic and Safety Roles in Laparoscopic Versus Abdominal Radical Hysterectomy in Cervical Cancer: A Meta-analysis. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2015, 25, 990-998.	1.0	83
3	High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0167449.	2.5	45
4	Prognostic value of prostaglandin I2 synthase and its correlation with tumor-infiltrating immune cells in lung cancer, ovarian cancer, and gastric cancer. Aging, 2020, 12, 9658-9685.	3.1	30
5	Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. Journal of Gynecologic Oncology, 2015, 26, 111.	2.2	25
6	Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Journal of Gynecologic Oncology, 2020, 31, e86.	2.2	22
7	GOLPH3L is a Novel Prognostic Biomarker for Epithelial Ovarian Cancer. Journal of Cancer, 2015, 6, 893-900.	2.5	16
8	Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncolmmunology, 2019, 8, e1528411.	4.6	16
9	Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis. Advances in Therapy, 2019, 36, 3368-3380.	2.9	14
10	The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e40.	2.2	12
11	Neoadjuvant chemotherapy followed by conization to spare fertility in cases of locally advanced cervical cancer: A case report and review of the literature. Molecular and Clinical Oncology, 2016, 5, 411-416.	1.0	8
12	The Role of GOLPH3L in the Prognosis and NACT response in Cervical Cancer. Journal of Cancer, 2017, 8, 443-454.	2.5	6
13	Minimally invasive surgery vs laparotomy for early stage cervical cancer: A propensity scoreâ€matched cohort study. Cancer Medicine, 2020, 9, 9236-9245.	2.8	6
14	A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of Gynecologic Oncology, 2020, 31, e61.	2.2	6
15	Perineural Invasion Should Be Regarded as an Intermediate-Risk Factor for Recurrence in Surgically Treated Cervical Cancer: A Propensity Score Matching Study. Disease Markers, 2021, 2021, 1-8.	1.3	5
16	Potential risks in sentinel lymph node biopsy for cervical cancer: a single-institution pilot study. World Journal of Surgical Oncology, 2020, 18, 133.	1.9	4
17	The outcome and efficacy of adjuvant chemotherapy alone in patients with stage IIIA endometrial carcinoma with solitary adnexal involvement: A retrospective single-institution study. Gynecologic Oncology, 2014, 135, 446-450.	1.4	3
18	Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of Gynecologic Oncology, 2022, 33, .	2.2	1

#	Article	IF	CITATIONS
19	Preoperative Evaluation of Perineural Invasion in Cervical Cancer: Development and Independent Validation of a Novel Predictive Nomogram. Frontiers in Oncology, 2021, 11, 774459.	2.8	O